Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Minocycline hydrochloride
As low as
71
CHF
CHF 71.00
In stock
Only %1 left
CDX-M0620-M250250 mgCHF 71.00
CDX-M0620-G0011 gCHF 155.00
NEW

Product Details | |
---|---|
Synonyms | MinCyc; Minomycin; Klinomycin; Minocin; NSC141993 |
Product Type | Chemical |
Properties | |
Formula | C23H27N3O7 . HCl |
MW | 493.94 |
CAS | 13614-98-7 |
RTECS | QI7630500 |
Source/Host Chemicals | Synthetic |
Purity Chemicals | ≥98% (HPLC) |
Appearance | Yellow powder. |
Solubility | Soluble in DMSO (30mg/ml), DMF, methanol or water (5mg/ml). |
Identity | Determined by 1H-NMR. |
Declaration | Manufactured by Chemodex. |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
InChi Key | GLMUAFMGXXHGLU-VQAITOIOSA-N |
Smiles | CN(C)[C@H](C(O)=C1C(N)=O)[C@@]2([H])[C@@](C(O)=C(C(C3=C(O)C=CC(N(C)C)=C3C4)=O)[C@]4([H])C2)(O)C1=O.Cl |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +20°C |
Long Term Storage | +4°C |
Handling Advice | Protect from light and moisture. |
Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
Documents | |
Product Specification Sheet | |
Datasheet |
![]() |
Description
Minocycline, a semi-synthetic second-generation tetracycline, is a broad spectrum antibiotic with bacteriostatic function. Tetracyclines, including minocycline, function by binding to the 30S ribosomal subunit, thereby preventing charged tRNA from delivering amino acids to elongate the protein chain and form cellular protein. This disruption results in a bacteriostatic effect on the prokaryotic cell, leading to the loss of its ability to grow or replicate. Being lipid-soluble compounds, tetracyclines can traverse hydrophobic barriers such as biological membranes. It is orally active and brain penetrant. Apart from its efficacy against gram-positive and gram-negative bacteria, minocycline also exhibits antioxidant, anti-apoptotic, anti-tumor, anti-inflammatory, immunomodulatory, and neuroprotective properties. Minocycline has anti-inflammatory properties and inhibits neuroinflammation in pre-plaque of Alzheimer's disease-like amyloid pathology through inhibition of key inflammatory enzymes like inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP-9) and 5-lipoxygenase. Minocycline inhibits endothelial cell proliferation and angiogenesis, and inhibit the enzymatic activity of poly(ADP-ribose) polymerase-1 (PARP-1). Minocycline exhibits anti-tumor activity in glioma by inhibiting membrane type 1 matrix metalloproteinase (MT1-MMP). Minocycline increases cognition and neuronal differentiation.
Product References
(1) R.J. Tamargo, et al.; Cancer Res. 51, 672 (1991) | (2) S. Gilbertson-Beadling, et al.; Cancer Chemother. Pharmacol. 36, 418 (1995) | (3) M. Kloppenburg, et al.; Clin. Exp. Immunol. 102, 635 (1995) | (4) S. Parangi, et al.; PNAS 93, 2002 (1996) | (5) T. Tikka, et al.; J. Neurosci. 21, 2580 (2001) | (6) V. Brundula, et al.; Brain 125, 1297 (2002) | (7) F. Giuliani, et al.; J. Leukoc. Biol. 78, 135 (2005) | (8) M.C. Zink, et al.; JAMA 293, 2003 (2005) | (9) S.S.V. Padi & S.K. Kulkarni; Eur. J. Pharmacol. 601, 79 (2008) | (10) R. Tao, et al.; J. Cardiovasc. Pharmacol. 56, 659 (2010) | (11) N. Garrido-Mesa, et al.; Pharmacol. Res. 67, 18 (2013) | (12) N. Garrido-Mesa, et al.; Br. J. Pharmacol. 169, 337 (2013) | (13) D.J. Ritchie & A. Garavaglia-Wilson; Clin. Infect. Dis. 59, S374 (2014) | (14) O.M. Dean, et al.; Clin. Psychopharmacol. Neurosci. 12, 180 (2014) | (15) J.A. Brenes-Salazar; Can. J. Physiol. Pharmacol. 93, 863 (2015) | (16) J. Budni, et al.; Curr. Alzheimer Res. 13, 1319 (2016) | (17) A.R. Afshari, et al.; J. Oncol. 2020, 8659802 (2020) | (18) D.A. Shin, et al.; J. Pain Res. 14, 139 (2021) | (19) S. Singh, et al.; Curr. Mol. Pharmacol. 14, 1046 (2021) | (20) A. Rezaei, et al.; Naunyn Schmiedebergs Arch. Pharmacol. 397, 2835 (2024)